For the year ended 31 March 2014, impairment losses rec- ognised for other intangible assets were ¥53,892 million, and  the details of the main items are as follows: and other marketing rights as the profitability was lower  than originally expected. Significant intangible assets recognised in the consolidated  statements of financial position are mainly composed of the  rights related to “Tarceva” resulting from the acquisition of OSI  Pharmaceuticals, Inc. in 2010 and ones related to the acquired  research and development project of ASP1517/yM311  through the license agreement with FibroGen, Inc. The carrying  amounts of those intangible assets as of 31 March 2014 were  ¥96,108 million and ¥50,565 million (¥120,905 million and  ¥49,343 million as of 31 March 2013), respectively. The  remaining amortisation period of intangible assets associated  with the marketed products is mainly 5 to 6 years, and the  intangible assets not yet being amortised are tested for  impairment annually. Significant intangible assets (i) Impairment losses of ¥40,191 million were mainly recog- nised due to the discontinuation of development activities  for IPR&Ds. This includes the discontinuation of develop- ment of ASP2408 (Rheumatoid arthritis), ASP2409  (Prevention of organ transplant rejection), the discontinua- tion of development or clinical studies of non-small cell  lung cancer (Adjuvant, combination with MetMAb) of  erlotinib (Tarceva), termination of the license agreement  with AVEO about tivozanib (renal cell carcinoma, colorec- tal cancer, breast cancer), and the amendment of the  license agreement with Basilea about isavconazole (azole  antifungal) and others. (ii) Impairment losses of ¥11,296 million were recognised  due to revising sales projections downwards for DIFICLIR  sold in Europe for clostridium difficile infection treatment  18. DeferreD taxes The breakdown and movement of deferred tax assets and deferred tax liabilities are as follows: (Millions of yen) As of 1 April 2012 Recognised in  profit or loss Recognised in  other comprehensive  income Other As of 31 March 2013 Deferred tax assets Available-for-sale financial assets ¥ 2,155 ¥ (848) ¥ — ¥ 0 ¥ 1,307 Retirement benefit liabilities 9,284 (626) 2,125 270 11,054 Property, plant and equipment 6,828 139 — 203 7,170 Intangible assets 38,103 (5,254) — 373 33,221 Accrued expenses 15,139 1,988 — 1,261 18,389 Inventories 31,217 4,268 — 711 36,195 Tax loss carry-forwards 3,237 (2,155) — 180 1,263 Other 63,022 (22,631) — 944 41,335 Total deferred tax assets 168,986 (25,120) 2,125 3,943 149,934 Deferred tax liabilities Available-for-sale financial assets (10,372) — (1,785) — (12,157) Property, plant and equipment (585) (554) — (157) (1,297) Intangible assets (105,589) 18,279 — (5,573) (92,883) Other (12,590) (931) — (168) (13,689) Total deferred tax liabilities (129,137) 16,794 (1,785) (5,898) (120,026) Net deferred tax assets (liabilities) ¥ 39,849 ¥ (8,326) ¥ 340 ¥(1,956) ¥ 29,908 For the year ended 31 March 2013 Astellas Pharma Inc.  _ Annual Report 2014 126